Lilly Strategy: Timely, Valued Medicines to Patients

Dec 02, 2013
By Pharmaceutical Technology Editors

Dr. Jan Lundberg, EVP science and technology and president Lilly Research Labs, Lilly & Co., sits down to discuss the company’s new approach to drug development and its Phase III pipeline.

For more videos tune in to:

lorem ipsum